Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL study
Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL study. // International Journal of Lung Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000549?dgcid=rss_sd_all
Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL study. International Journal of Lung Cancer. https://www.sciencedirect.com/science/article/pii/S3117504X26000549?dgcid=rss_sd_all
“Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL study.” International Journal of Lung Cancer.
@article{article50010,
title = {Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL study},
journal = {International Journal of Lung Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000549?dgcid=rss_sd_all}
}